0

Prils Market by Application and Geography - Forecast and Analysis 2022-2026

  • Published: Jan 2022
  • Pages: 120
  • SKU: IRTNTR71962
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The prils market share is expected to increase by USD 784.14 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 5.43%.

This prils market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers prils market segmentation by application (hypertension, heart failure, and chronic kidney disorders) and geography (North America, Europe, Asia, and ROW). The prils market report also offers information on several market vendors, including Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Fazio Group of Companies, Lupin Ltd., Manus Aktteva Biopharma LLP, Merck KGaA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Viatris Inc. among others.

What will the Prils Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Prils Market Size for the Forecast Period and Other Important Statistics

 

Prils Market: Key Drivers and Challenges

The rising geriatric population is notably driving the prils market growth, although factors such as side effects of prils may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the prils industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Prils Market Driver

The rising geriatric population is one of the key factors driving the global prils market growth. The increase in the aging population is a matter of concern for many countries such as China, US, and Japan. This growing population requires medical services, which in turn will positively impact the market in focus during the forecast period. For instance, the high incidence of cardiovascular diseases (CVDs) in the US is leading to a high rise in the consumption of CVD drugs. The governments are increasing the investment in R&D in hypertension and cardiovascular segment which will drive the global prils market growth. Furthermore, certain chronic diseases such as obesity, diabetes, and high cholesterol will increase the risk of heart disease, thereby increasing the demand for CVD drugs and further stimulating the growth.

Key Prils Market Challenge

One of the key challenges to the global prils market growth is the side effects of prils. The drugs used for the treatment of heart failure and hypertension have many side effects such as dizziness, ringing or buzzing in the ears, diarrhea, high potassium levels in the blood, which can cause heart rhythm problems, and swelling due to fluid buildup under the skin. This will encourage consumers to adopt other modes of management of diseases, such as maintaining a healthy lifestyle with proper diets and exercise. Therefore, such negative impacts of prils on patients and availability of a wide range of substitutes may reduce the adoption of prils for heart treatment in the market in focus during the forecast period.

This prils market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Who are the Major Prils Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Aurobindo Pharma Ltd.
  • Dr. Reddys Laboratories Ltd.
  • Fazio Group of Companies
  • Lupin Ltd.
  • Manus Aktteva Biopharma LLP
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.

 

This statistical study of the prils market encompasses successful business strategies deployed by the key vendors. The prils market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The prils market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Which are the Key Regions for Prils Market?

For more insights on the market share of various regions Request for a FREE sample now!

40% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for prils in North America. Market growth in this region will be slower than the growth of the market in Asia and Europe.

The significant increase in the geriatric population and high demand for CVD drugs for the treatment of cardiovascular diseases (CVDs) will facilitate the prils market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Application Segments in the Prils Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The prils market share growth by the hypertension segment will be significant during the forecast period. This report provides an accurate prediction of the contribution of all the segments to the growth of the prils market size and actionable market insights on post COVID-19 impact on each segment.

 

Prils Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 5.43%

Market growth 2022-2026

$ 784.14 million

Market structure

Fragmented

YoY growth (%)

4.15

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 40%

Key consumer countries

US, Canada, Germany, China, and UK

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Fazio Group of Companies, Lupin Ltd., Manus Aktteva Biopharma LLP, Merck KGaA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Prils Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive prils market growth during the next five years
  • Precise estimation of the prils market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the prils industry across North America, Europe, Asia, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of prils market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

Executive Summary

    Market Landscape

    • Market ecosystem
    • Value chain analysis

    Market Sizing

    • Market definition
    • Market segment analysis
    • Market size 2021
    • Market outlook: Forecast for 2021 - 2026

    Five Forces Analysis

    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition

    Market Segmentation by Application

    • Market segments
    • Comparison by Application
    • Hypertension - Market size and forecast 2021-2026
    • Heart failure - Market size and forecast 2021-2026
    • Chronic kidney disorders - Market size and forecast 2021-2026
    • Market opportunity by Application

    Customer landscape

      Geographic Landscape

      • Geographic segmentation
      • Geographic comparison
      • North America - Market size and forecast 2021-2026
      • Europe - Market size and forecast 2021-2026
      • Asia - Market size and forecast 2021-2026
      • ROW - Market size and forecast 2021-2026
      • Key leading countries
      • Market opportunity by geography
      • Market drivers
      • Market challenges
      • Market trends

      Vendor Landscape

      • Vendor Landscape
      • Landscape disruption

      Vendor Analysis

      • Vendors covered
      • Market positioning of vendors
      • Aurobindo Pharma Ltd.
      • Dr. Reddys Laboratories Ltd.
      • Fazio Group of Companies
      • Lupin Ltd.
      • Manus Aktteva Biopharma LLP
      • Merck KGaA
      • Novartis AG
      • Pfizer Inc.
      • Sun Pharmaceutical Industries Ltd.
      • Viatris Inc.

      Appendix

      • Scope of the report
      • Currency conversion rates for US$
      • Research methodology
      • List of abbreviations

      Research Framework

      Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

      TechnavioINFORMATION SOURCES

      Primary sources

      • Manufacturers and suppliers
      • Channel partners
      • Industry experts
      • Strategic decision makers

      Secondary sources

      • Industry journals and periodicals
      • Government data
      • Financial reports of key industry players
      • Historical data
      • Press releases
      Technavio

      TechnavioDATA ANALYSIS

      Data Synthesis

      • Collation of data
      • Estimation of key figures
      • Analysis of derived insights

      Data Validation

      • Triangulation with data models
      • Reference against proprietary databases
      • Corroboration with industry experts
      Technavio

      TechnavioREPORT WRITING

      Qualitative

      • Market drivers
      • Market challenges
      • Market trends
      • Five forces analysis

      Quantitative

      • Market size and forecast
      • Market segmentation
      • Geographical insights
      • Competitive landscape
      Interested in this report?
      Get your FREE sample now!
      The prils market growth will increase by $784.14 million during 2021-2026.
      The prils market is expected to grow at a CAGR of 5.43% during 2021-2026.
      Technavio has segmented the prils market by application (Hypertension, Heart failure, and Chronic kidney disorders) and geographic (North America, Europe, Asia, and ROW).
      Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Fazio Group of Companies, Lupin Ltd., Manus Aktteva Biopharma LLP, Merck KGaA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc. are a few of the key vendors in the prils market.
      North America will register the highest growth rate of 40.17% among the other regions. Therefore, the prils market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
      • US
      • Canada
      • Germany
      • China
      • UK
      The key factors driving the prils market growth are:
      • Rising geriatric population
      The prils market vendors should focus on grabbing business opportunities from the hypertension segment as it accounted for the largest market share in the base year.
      Safe and Secure SSL Encrypted
      Technavio

      Single User:

      2500 USD

      Technavio Get the report (PDF) sent to your email within minutes.

      Subscribe & Save

      Get lifetime access to our
      Technavio Insights

      Want to customize this report?

      This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

      We offer $1000 worth of FREE customization at the time of purchase
      Technavio
      Enquire Before Buying
      1. Home
      2. Health Care
      3. Published Report
      17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>